| [1] | BLAESE RM, ANDERSON WF. The ADA human gene therapy clinical protocol[J]. Hum Gene Ther,1990,1(3):327-362. doi: 10.1089/hum.1990.1.3-327 |
| [2] | LU D R, ZHOU J M, ZHENG B, et al. Stage I clinical trial of gene therapy for hemophilia B[J]. Sci China B,1993,36(11):1342-1351. |
| [3] | 关大刚, 郑旭. 重组人p53腺病毒注射液(今又生)临床研究进展[J]. 现代肿瘤医学, 2011, 19(12):2560-2563. doi: 10.3969/j.issn.1672-4992.2011.12.69 |
| [4] | CYRANOSKI D. CRISPR gene-editing tested in a person for the first time[J]. Nature,2016,539(7630):479. doi: 10.1038/nature.2016.20988 |
| [5] | 张岩松, 陈丽娇, 张婷, 等. 基因治疗的研究进展[J]. 中国细胞生物学学报, 2020, 42(10):1858-1869. |
| [6] | WANG D W, WANG K, CAI Y J. An overview of development in gene therapeutics in China[J]. Gene Ther,2020,27(7-8):338-348. doi: 10.1038/s41434-020-0163-7 |
| [7] | DUNBAR C E, HIGH K A, JOUNG J K, et al. Gene therapy comes of age[J]. Science,2018,359(6372):eaan4672. doi: 10.1126/science.aan4672 |
| [8] | STEFFIN D H M, HSIEH E M, ROUCE R H. Gene therapy: current applications and future possibilities[J]. Adv Pediatr,2019,66:37-54. doi: 10.1016/j.yapd.2019.04.001 |
| [9] | NATHWANI A C, DAVIDOFF A M, TUDDENHAM E G D. Gene therapy for hemophilia[J]. Hematol Clin N Am,2017,31(5):853-868. doi: 10.1016/j.hoc.2017.06.011 |
| [10] | ROSSIDIS A C, STRATIGIS J D, CHADWICK A C, et al. In utero CRISPR-mediated therapeutic editing of metabolic genes[J]. Nat Med,2018,24(10):1513-1518. doi: 10.1038/s41591-018-0184-6 |
| [11] | ANZALONE A V, RANDOLPH P B, DAVIS J R, et al. Search-and-replace genome editing without double-strand breaks or donor DNA[J]. Nature,2019,576(7785):149-157. doi: 10.1038/s41586-019-1711-4 |
| [12] | RYU S M, KOO T, KIM K, et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy[J]. Nat Biotechnol,2018,36(6):536-539. doi: 10.1038/nbt.4148 |
| [13] | RAN F A, CONG L, YAN W X, et al. In vivo genome editing using Staphylococcus aureus Cas9[J]. Nature,2015,520(7546):186-191. doi: 10.1038/nature14299 |
| [14] | GAO X, TAO Y, LAMAS V, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents[J]. Nature,2018,553(7687):217-221. doi: 10.1038/nature25164 |
| [15] | FOLDVARI M, CHEN D W, NAFISSI N, et al. Non-viral gene therapy: gains and challenges of non-invasive administration methods[J]. J Control Release,2016,240:165-190. doi: 10.1016/j.jconrel.2015.12.012 |
| [16] | DOUDNA J A. The promise and challenge of therapeutic genome editing[J]. Nature,2020,578(7794):229-236. doi: 10.1038/s41586-020-1978-5 |
| [17] | CONG L, RAN F A, COX D, et al. Multiplex genome engineering using CRISPR/Cas systems[J]. Science,2013,339(6121):819-823. doi: 10.1126/science.1231143 |
| [18] | JUNE C H, O'CONNOR R S, KAWALEKAR O U, et al. CAR T cell immunotherapy for human cancer[J]. Science,2018,359(6382):1361-1365. doi: 10.1126/science.aar6711 |
| [19] | LUNDSTROM K. Viral vectors in gene therapy[J]. Diseases,2018,6(2):42. doi: 10.3390/diseases6020042 |
| [20] | ZEBALLOS D M A, GAJ T. Next-generation CRISPR technologies and their applications in gene and cell therapy[J]. Trends Biotechnol,2021,39(7):692-705. doi: 10.1016/j.tibtech.2020.10.010 |
| [21] | TAGUCHI S, FUKUHARA H, TODO T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives[J]. Jpn J Clin Oncol,2019,49(3):201-209. doi: 10.1093/jjco/hyy170 |
| [22] | 杨若南, 许丽, 徐萍, 等. RNA疗法产业发展态势分析及建议[J].中国生物工程杂志, 2021, 41(2): 162-171. |